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One of the barriers to the development of protein therapeutics is effective delivery to mammalian cells.
The proteins must maintain a careful balance of polar moieties to enable administration and distribution
and hydrophobic character to minimize cell toxicity. Numerous strategies have been applied to this end,
from appending additional cationic peptides to supercharging the protein itself, sometimes with limited
success. Here we present a strategy that combines these methods, by equipping a protein with super-
charged elastin-like polypeptide (ELP) tags. We monitored cellular uptake and cell viability for GFP re-
porter proteins outﬁtted with a range of ELP tags and demonstrated enhanced uptake that correlates
with the number of positive charges, while maintaining remarkably low cytotoxicity and resistance to
degradation in the cell. GFP uptake proceeded mainly through caveolae-mediated endocytosis and we
observed GFP emission inside the cells over extended time (up to 48 h). Low toxicity combined with high
molecular weights of the tag opens the way to simultaneously optimize cell uptake and pharmacokinetic
parameters. Thus, cationic supercharged ELP tags show great potential to improve the therapeutic proﬁle
of protein drugs leading to more efﬁcient and safer biotherapeutics.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
The application of proteins for therapy represents an emerging
area and until now, around 180 protein drugs have been clinically
approved including insulin, erythropoietin, interferons, and a va-
riety of antibodies [1]. In contrast to small molecule drugs, thera-
peutic proteins are generally considered as biocompatible with
higher speciﬁcity for their respective target. Until now, most pro-
tein therapeutics mainly address extracellular targets since exog-
enous proteins are typically not able to diffuse into cells [2]. The
pharmacokinetic properties and bioavailability of drugs critically
depend on their molecular weight and their ability to overcome
cellular membranes. As a consequence, many promising drug
candidates fail to advance in the clinic since they do not fulﬁll the
structural requirements needed for cellular uptake; either they are
too hydrophobic for administration and distribution or they are too
polar or of too high molecular weight for passive cellular entry. The
latter holds particularly true for protein therapeutics.
Over the past decade, a variety of reagents have been developed
to allow the delivery of proteins into mammalian cells includingWeil), a.herrmann@rug.nl
All rights reserved.lipid-linked compounds [3], nanoparticles [4], cationic peptides [5]
and fusions to receptor ligands [6] like the protein transduction
domains (PTDs) including the HIV-1 transactivator of transcription
(Tat) peptide, oligoarginine, the Drosophila Antennapedia-derived
penetratin peptide [7] and the (antiapoptotic) pentapeptides
derived from the Bax binding domain of Ku70 [8]. These cell pene-
trating peptides (CPPs) can trigger the transfer of a cargo across the
cell membrane into the cytoplasm. They are typically characterized
byan amino acid composition that either contains a high abundance
of positively charged amino acids such as lysine or arginine (poly-
cationic) or exhibits an alternating pattern of polar/charged and
non-polar, hydrophobic residues (amphiphilic). A typical poly-
cationic peptide is poly-L-lysine (PLL), which has been used to efﬁ-
ciently deliver a range of biomolecules into cells including albumin
and horseradish peroxidase [9]. Poly-L-arginine (PLA), a motif
inspired by the naturally occurring CPPs, has beenwidely used both
in vitro for the transfer of peptides [10] and in vivo for the delivery of
proteins [11]. Arg7 and Arg9 have been used in vivo for the transfer
of cyclosporine [12] and human catalase [13], respectively. Several
experimental and theoretical studies were carried out to elucidate
the mechanism for translocation of CPPs and to investigate the role
of different positively charged amino acid residues [14,15]. However,
it was also demonstrated that polycations can induce toxicity such
as mitochondria-mediated apoptosis [16].
Rather than appending a polycationic peptide, another strategy
for introducing positive charges is increasing the net charge of a
D. Pesce et al. / Biomaterials 34 (2013) 4360e4367 4361polypeptide chain (henceforward called “supercharging”). This
process enhances solubility and causes intermolecular repulsion
even in the unfolded state, which in turn prevents aggregation [17].
Fusion to supercharged polypeptides enhances protein delivery
in vitro and in vivo in a process that is clathrin- and energy-
dependent, involving binding to anionic cell surface pro-
teoglycans and endocytosis [2]. Using this approach, potent de-
livery vectors were realized by a “supercharged” variant of GFP [18],
and by using a diverse class of naturally occurring supercharged
human proteins [19]. Nevertheless, when rational supercharging
was applied to other functional proteins like binding proteins
(streptavidin) and enzymes (glutathione S-transferase) the modi-
ﬁcations conferred increased thermal resistance but diminished
function [20]. The “supercharging” of a protein by genetic mutation
of surface-exposed amino acids requires, indeed, careful examina-
tion of the crystal structure to identify charged amino acid residues
on the protein surface, mutation and shufﬂing of the gene
sequence, and expression and screening for functional variants [2].
Moreover, it is not guaranteed that this process creates a functional
variant with a certain desired surface charge.
We have previously reported the fabrication of unfolded
supercharged polypeptides designed with elastin-like polypeptide
(ELP) as the basic sequence [21]. These materials can be positively
and negatively “supercharged” in a straightforward manner by
introducing a lysine or glutamic acid residue at the second position
of the repetitive pentapeptide sequence (GVGVP) [21]. This enables
us to tune the overall charge of the protein by simply adjusting the
length of the tag while obviating modiﬁcation of the protein itself.
At the same time, the lower charge density of the backbone in these
ELP tags compared to other polycationic polymers such as poly-
arginine decreases cytotoxicity [21]. The suitability of neutral or
weakly charged ELPs as materials for biomedical applications has
been demonstrated in a number of publications. ELPs were
employed as hydrogels for biosurface and tissue engineering [22]
and for controlled release [23,24]. Furthermore, ELPs have been
already used for delivery of drugs, peptides, proteins and DNA [24e
26] and included in modiﬁed liposomes they enhance cellular up-
take into tumor cells [27].
Thus positively supercharged tags based on ELP could be a
suitable tool for facilitating cellular uptake of active proteins. In this
contribution we tested whether positively “supercharged” ELP tags
can serve as a platform for the delivery of proteins into mammalian
cells, without altering their properties. Therefore, GFP was selected
as a reporter protein and the cellular uptake of a functional variant
of GFP fused to positively charged cationic ELP tags, with different
numbers of charges (ranging from 9 to 72), was studied using an
in vitro cell culture lung cell model (A549). Moreover, cell toxicity
and cellular uptake mechanisms were investigated.2. Materials and methods
2.1. Cloning and expression of GFP equipped with supercharged ELP tags
Monomers of the cationic and anionic ELP genes (K9 and E9) were ordered from
Entelechon and were delivered in the pEN vector. Gene sequences and respective
amino acid sequences of monomers are shown in Fig. S1. As the recognition sites of
the restriction enzymes PﬂMI and BglI had to be preserved, one valine residue per
ten pentapeptide repeats was incorporated instead of a lysine or glutamic acid
residue. The ELP gene was excised from the pEN vector by digestion with EcoRI and
HinDIII (Fermentas, St. Leon-Rot, Germany) and run on a 1% agarose gel (Sigmae
Aldrich, St. Louis, MO) in TAE buffer (per 1 L, 108 g Tris base, 57.1 mL glacial acetic
acid, 0.05 M EDTA, pH 8.0). The band containing the ELP gene was excised from the
gel and puriﬁed using a spin column puriﬁcation kit (QIAGEN). PUC19 (Fermentas,
St. Leon-Rot, Germany) was digested with EcoRI and HinDIII and dephosphorylated.
The vector was puriﬁed by agarose gel extraction following gel electrophoresis. The
linearized pUC vector and the ELP-encoding gene were ligated and transformed into
XL1-Blue cells (Stratagene, Cedar Creek, TX). For transformation, 20 mL of chemically
competent Escherichia coli XL1-Blue cells were combined with 5 mL of the ligationmixture and further treated according to the manufacturer’s protocol. Cells were
spread on LB agar plates (for 1 L, 10 g Bacto tryptone, 5 g BBL yeast extract, 5 g
NaCl, 15 g agar) supplemented with 100 mg/mL carbenicillin (Carl Roth, Karlsruhe,
Germany), and incubated o/n at 37 C. Colonies were picked and grown in 6 mL LB
media (for 1 L, 10 g Bacto tryptone, 5 g BBL yeast extract, 5 g NaCl) (Becton,
Dickinson and Co. Sparks, MD) supplemented with 100 mg/mL carbenicillin o/n, and
plasmids were isolated using the Plasmid Miniprep kit (Fermentas, St. Leon-Rot,
Germany). Positive clones were veriﬁed by plasmid digestion with EcoRI and Hin-
DIII and the DNA sequence of putative inserts was further veriﬁed by DNA
sequencing (SequenceXS, Leiden, The Netherlands). Gene oligomerization was
performed as described by Chilkoti and co-workers (Fig. S2) [28].
The expression vector pET 25b(þ) (Novagen Inc., San Diego, CA) wasmodiﬁed by
cassette mutagenesis for incorporation of a unique SﬁI recognition site as described
before [21,28]. The modiﬁed pET 25b(þ) vector (henceforward called pET-SﬁI) was
further digested with XbaI and NdeI (Fermentas, St. Leon-Rot, Germany), dephos-
phorylated and puriﬁed by a spin column puriﬁcation kit. The GFP gene including
the ribosomal binding site was excised from the pGFP vector (pGFP was a kind gift
from Prof. D. Hilvert, Federal Institute of Technology, Zurich, Switzerland) by
digestion with XbaI and SacI (Fermentas, St. Leon-Rot, Germany), and the excised
gene (747 bp) was puriﬁed by agarose gel electrophoresis. A linker sequence that
connects GFP and the SﬁI restriction site was constructed in the following way:
Oligonucleotides (SigmaeAldrich, St. Louis, MO) linker_sens (cggtgtagtc ggtttagttc
ccagaggaag tca) and linker_antisens (tatgacttcc tctgggaact aaaccgacta caccgagct),
both 50-phosphorylated, were mixed in equimolar ratios, incubated at 90 C for 1 h
and then cooled down stepwise to 20 C for annealing (1 C per 3min). The resulting
linker contained overhangs corresponding to a SacI and an NdeI restriction site,
respectively. pET-SﬁI, the insert containing GFP and the linker were ligated, yielding
pET-GFP-SﬁI. For insertion of ELP genes, pET-GFP-SﬁI was digested with SﬁI,
dephosphorylated and puriﬁed using a microcentrifuge spin column kit. The
respective ELP gene was excised from the pUC19 vector by digestion with PﬂMI and
BglI, and the linearized vector and the insert containing the ELP gene were ligated,
transformed into XL1-Blue cells, and screened as described above.
E. coli BLR (DE3) cells (Novagen) were transformed with the pET-SﬁI expression
vectors containing the respective ELP genes. For protein production, Terriﬁc Broth
medium (for 1 L, 12 g tryptone and 24 g yeast extract) enriched with phosphate
buffer (for 1 L, 2.31 g potassium phosphate monobasic and 12.54 g potassium
phosphate dibasic) (Merck KGaA, Darmstadt, Germany) and glycerol (4 mL per
1 L TB) (Merck) and supplemented with 100 mg/mL ampicillin (Roth), was inoculated
with an o/n starter culture to an initial optical density at 600 nm (OD600) of 0.1 and
incubated at 37 C with orbital agitation at 250 rpm until OD600 reached 0.7. Protein
production was induced by a temperature shift to 30 C. Cultures were then
continued for additional 16 h post-induction. Cells were subsequently harvested by
centrifugation (7000 g, 20 min, 4 C), resuspended in lysis buffer (50 mM sodium
phosphate buffer, pH 8.0, 300 mM NaCl, 20 mM imidazole (Carl Roth, Karlsruhe,
Germany) for E variants or 10 mM TriseHCl buffer, pH 8.0, 300 mM NaCl, 20 mM
imidazole for K variants) to an OD600 of 100 and disrupted with a constant cell
disrupter (Constant Systems Ltd., Northands, UK). Cell debris was removed by
centrifugation (40,000 g, 90 min, 4 C). Proteins were puriﬁed from the superna-
tant under native conditions by Ni-sepharose chromatography (GE Healthcare).
Product-containing fractions were pooled and dialyzed against ultrapure water
(>18 MU). K variants were further puriﬁed by afﬁnity chromatography using a
Heparin HP column (GE Healthcare), and E variants by anion exchange chroma-
tography using a Q HP column (GE Healthcare). Protein-containing fractions were
dialyzed extensively against ultrapure water (>18 MU). Puriﬁed proteins were
frozen in liquid nitrogen, lyophilized and stored at 20 C until further use.
2.2. Protein characterization
The concentrations of the puriﬁed ELPs were determined by measuring absor-
bance at 280 nm using a SpectraMaxM2 (Molecular Devices, Sunnyvale, CA). Protein
purity was determined by sodium dodecyl sulfate polyacrylamide gel electropho-
resis (SDS-PAGE) on a 12% polyacrylamide gel (Bio-Rad Laboratories, Hercules, CA).
Gels were stained with Coomassie staining solution (40% methanol, 10% glacial
acetic acid, 1 g/L Brilliant Blue R250). Photographs of the gels were takenwith a LAS-
3000 Image Reader (Fuji Photo Film (Europe) GmbH, Dusseldorf, Germany).
Mass spectrometric analysis was performed using a 4800 MALDI-TOF/TOF
Analyzer (Applied Biosystems, Foster City, CA, USA) in the linear positive mode.
The protein samples were mixed 1:1 v/v with a recrystallized a-cyano-4-
hydroxycinnamic acid matrix (10 mg/mL in 50% ACN and 0.1% TFA, LaserBio Labs).
Mass spectra were analyzed and calibrated internally with the Data Explorer soft-
ware, version 4.9 (Applied Biosystems, Foster City, CA, USA). Trypsinogen
(Mw ¼ 23,980), enolase (Mw ¼ 46,672) (LaserBio Labs, Sophia-Antipolis, France) and
bovine serum albumin (Mw ¼ 66,431) (Carl Roth, Karlsruhe, Germany) were used as
calibration standards.
Fluorescence spectra of GFP, GFP-K72 and GFP-E72 were recorded on a Spec-
traMax M2 (Molecular Devices, Sunnyvale, CA). GFP concentration in phosphate
buffer solution (PBS) was determined by measuring absorbance at 488 nm. Volumes
were adjusted with PBS until absorbance at 488 nm was between 0.82 and 0.85.
Samples were diluted ten times in PBS for ﬂuorescencemeasurements. Fluorescence
Fig. 1. Characterization of GFP fusion variants of supercharged elastin-like proteins (A) schematic representation of GFPeELP fusion proteins. GFP (green) shows the characteristic
beta-barrel structure, whereas the ELP is presented as an extended coil (red) without exhibiting a deﬁned secondary or tertiary structure. (B) GFPeELP fusion proteins separated on
a 12% SDS-PAGE gel and stained with Coomassie brilliant blue R250. (C) MALDI-TOF mass spectra of supercharged elastin-like proteins fused to GFP. From top to bottom: GFP-K9;
GFP-K18; GFP-K36; GFP-K72; GFP-E36. Internal standards are enolase (GFP-K18), bovine serum albumin (GFP-E36, GFP-K36, GFP-K72) and trypsinogen (GFP-K9). (D) Fluorescence
spectra of GFP and GFPeELP variants GFP-K72 and GFP-E72 upon excitation at 488 nm. Spectra are averages of three measurements.
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Fig. 2. (A) The relative cell uptake ratio has been calculated compared to native GFP
uptake, which has been set to 1. Each column presents average value of 6 measure-
ments from two independent experiments. The error bar presents the standard de-
viation. (B) The cell viability of each sample has been calculated. Cells in blank samples
are considered as 100% viable. Each column presents the average value of 3 inde-
pendent measurements. The error bar presents the standard deviation. (C) Confocal
micrograph of A549 cells incubated with 1 mM of GFP-K72 at 24 and 48 h.
D. Pesce et al. / Biomaterials 34 (2013) 4360e4367 4363spectrawere recorded upon excitation at 488 nm.Measurementswere carried out in
triplicates and average ﬂuorescence values were corrected for differences in
absorbance according to RFUcorr ¼ RFUmeas/0.84/abs488, with RFUcorr being the
corrected relative ﬂuorescence unit (RFU), RFUmeas the measured RFU, and abs488
the measured absorbance at 488 nm of the ten times concentrated solution.
2.3. Cell culture
A549 cells, a human alveolar basal epithelial carcinoma cell line, were obtained
from DSMZ (German Collection of Microorganisms and Cell Cultures, Braunsch-
weig). Cells were cultured in high-glucose DMEM (Dulbecco’s Modiﬁed Eagle Me-
dium) supplementedwith 10% fetal bovine serum (FBS), 100 U/mL penicillin, 0.1 mg/
mL streptomycin, and 0.1 mM non-essential amino acids at 37 C in a humidiﬁed 5%
CO2 incubator.
2.4. Quantiﬁcation of cell uptake
A549 cells were seeded in a 96-well microplate at a concentration of
80,000 cells/well. After overnight culture, the cells were incubated with 1 mM of
different GFP variants in 100 mL fresh medium for 24 h. The cells were then washed
three times with ice-cold PBS to remove the non-internalized samples and lysed
with 100 mL of lysis buffer (50 mM Tris, 0.8% Triton, 0.2% SDS, pH 7.4) [29]. Cell-
associated GFP was determined by measuring the ﬂuorescence of the lysate using
a TECAN InﬁniteM1000microplate reader (Ex 488 nm and Em 510 nm) [30]. All data
were collected in triplicate and two independent experiments were performed to
calculate the average cellular uptake.
2.5. Confocal microscopy
A549 cells were plated in a Coverglass Lab-Tek 8-well chamber and incubated
overnight to allow adhesion. The next day, fresh medium with 1 mM of GFP variants
were added to the cells and further incubated for 24 h. Before imaging, cells were
washed with PBS buffer three times and then the cell membrane was stained with
CellMask Deep Red plasma membrane stain for 5 min. Imaging was performed
using an LSM 710 laser scanning confocal microscope system (Zeiss, Germany)
coupled to an XL-LSM 710 S incubator and equipped with a 63 oil immersion
objective. The GFP variants were excited with a 488 nm argon laser and detected
after a 493 nme599 nm emission ﬁlter. The membrane stain was excited with a
HeNe laser (emission wavelength 633 nm) and detected after a 647 nme759 nm
emission ﬁlter. During the experiments, the samples were mounted on a
temperature-controlled microscope stage, which kept the cells at 37 C.
2.6. Cytotoxicity assay
Eight thousand A549 cells per well were plated onto a white 96-well plate and
incubated overnight to allow attachment. The wells were 70e80% conﬂuent on the
day of the experiment. The cells were treated with 1, 5 and 10 mM GFP variants or
1 mM doxorubicin as a positive control and incubated for another 24 h. Blank cells
without treatment were used to obtain 100% cell viability. After treatment, the Cell-
Titer Glo (Promega) cell viability assay kit was used to quantify the viability of the
cells in each well according to the manufacturer’s instructions.
2.7. Exploring uptake pathways using different endocytosis inhibitors
The cells were pre-incubated for 30 min with the following inhibitors: (i) 10 mg/
mL and 1 mg/mL of chlorpromazine to inhibit clathrin-mediated endocytosis, (ii)
1 mg/mL and 0.1 mg/mL of ﬁlipin to inhibit caveolae-mediated endocytosis, (iii) 40 mM
and 5 mM of amiloride to inhibit macropinocytosis. (All inhibitors were obtained from
SigmaeAldrich.) Each concentration of the inhibitors was chosen based on previous
studies [31e33] and it was also observed that at these concentrations, greater than
80% of the cells were viable by Cell-Titer Glo (Promega) cell viability assay. Sub-
sequently, the different GFP variants (1 mM) were added to the supernatant con-
taining the inhibitors and the cells were incubated at 37 C for 2 h. The cell uptake
was then quantiﬁed using ﬂuorescence as mentioned above. Under the same inhi-
bition conditions, cell uptake of endocytosis markers (Alex-488 transferrin as
clathrin-mediated endocytosis marker [33], BODIPYelactosylceramide as caveolae-
mediated endocytosis marker [34], FITCedextran as macropinocytosis marker [31])
were inhibited by >80%. The effect of temperature block was studied by pre-
incubating the cells at 4 C for 30 min and treatment with GFP variants (1 mM) for
2 h at 4 C.
2.8. Statistical analysis
Statistical signiﬁcance of the observed differences was evaluated by a one-way
ANOVA test followed by Dunnett’s test. A value of P < 0.05 was considered
signiﬁcant.3. Results and discussion
3.1. Preparation and characterization of supercharged GFPeELP
fusion proteins
Genes encoding for cationic and anionic supercharged protein
tags of different lengths were generated by recursive directional
ligation of the ELP monomer gene (Fig. S1) [27]. An ELP monomer
consists of 10 repeating units of the pentapeptide sequence GXGVP,
with G denoting the amino acid glycine, V valine, P proline and X
Fig. 3. Confocal microscope imaging of A549 cells incubated with 1 mM GFP derivatives for 24 h. Arrows indicate membrane aggregation.
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that is needed for multimerization, V is inserted at position X in one
out of ten pentapeptide repeats (Fig. 1A). After multimerization, the
ELP genes were cloned into a bacterial expression vector containing
theGFP gene anda sequence encoding a hexahistidine tag for afﬁnity
puriﬁcation. GFP encodes GFP plus, a variant of enhanced green
ﬂuorescent protein, hereafter named GFP (Fig. S3). We realized
fusion variants of GFP with supercharged protein tags containing
between9 and72positive charges andonewith 36 negative charges.
The exact sequence composition for the positive variants were Ne
GFPeGAGP[GVGVP(GKGVP)9]nGWPH6eC (with n ranging from 1 to
8) while the negatively charged fusion construct exhibited the
sequence NeGFPeGAGP[GVGVP(GEGVP)9]4GWPH6eC (Fig. 1A). In
this work, GFP-Ex and GFP-Kx denote GFP with anionic and cationic
tags, respectively, with x displaying the number of charged residues
in the tag. All variants were successfully expressed in and puriﬁed
from E. coli cells. Typically, a 50 mL culture yielded up to 1 mg of
puriﬁed protein. Molecular weight and purity were conﬁrmed by gel
electrophoresis (Fig. 1B) and mass spectrometry (Fig. 1C). Values
determined bymass spectrometrywere in good agreement with the
masses that were calculated based on the amino acid sequence
(Table S1). For all variants, GFP was found to be ﬂuorescent. Fluo-
rescence spectra were recorded for GFP, GFP-K72 and GFP-E36 (the
longest charged chains we realized) (Fig. 1D). GFP ﬂuorescence was
not decreased or shifted, indicating that even the long positively and
negatively charged tags did not interfere with GFP function. A
schematic representation of GFPeELP fusionproteins (Fig.1A) shows
GFP (green) drawn with its characteristic beta-barrel structure,
whereas the ELP is presented as an extended coil (red) without
exhibiting a deﬁned secondary or tertiary structure, as was demon-
strated previously [21].
3.2. Cellular uptake of supercharged GFPeELP fusion proteins
The inﬂuence of these tags on the in vitro cellular uptake of the
GFP fusion variants was studied with a representative mammalian
cell line (A549). The uptake of the various GFP species was quan-
tiﬁed by ﬂuorimetry [29,35] and a charge dependent cellular up-
take was clearly observed. The fusion of the negatively charged
elastin tag with 36 charges to GFP (GFP-E36) had no inﬂuence on
internalization compared to the unmodiﬁed GFP (Fig. 2A). In
contrast, pronounced cellular uptake for all positively supercharged
GFP variants compared to the control protein was detected.
Notably, the internalization increased with increasing the number
of positive charges within the supercharged tags. GFP-K9 uptake
doubled while GFP-K72 was incorporated six times more efﬁciently
than pristine GFP (Fig. 2A). Previously, neutral elastin-likepolypeptides were employed as delivery vehicles for small thera-
peutic peptides [36] and proteins [37]. However, with those sys-
tems uptake into cancerous tissue and cells was mediated by
exploiting their thermoresponsive properties and fused CCPmotifs,
respectively. Both features are not present in our supercharged ELP
variants systems indicating that we pursue a new paradigm for
cellular uptake regarding ELPs. In the context of charge dependent
uptake with supercharged ELP tags signiﬁcant differences to
supercharged GFPwhere lysine and arginine residues are present at
the surface of the protein were also revealed. With this super-
charged GFP variants a high-potency uptake regime was observed
at a theoretical positive net charge of 22 with no signiﬁcant
improvement of uptake when the number of charges is further
increased [38]. In contrast, we detected a delivery potency increase
even up to 72 theoretical net charges.
3.3. Intracellular localization
In the next step the intracellular localization of the GFP de-
rivatives was assessed using confocal ﬂuorescence microscopy
(Fig. 3). When A549 cells were incubated with GFP and GFP-E36 for
24 h, no signiﬁcant ﬂuorescence signal associated with the cells
was observed. However, when the cells were treated with the GFP-
K9 sample, GFP ﬂuorescence was mainly detected on the cell
membrane. In comparison, GFP-K18 was already observed inside
A549 cells, although some of the protein was still present as ag-
gregates on the cellular membrane. Such an aggregation behavior
has been reported previously for other positively charged macro-
molecules as well [39], indicating that a strong interaction between
the polycationic samples and the negatively charged cell mem-
brane represents a ﬁrst, essential step for interaction. Only GFP-K36
and GFP-K72 revealed signiﬁcant internalization and in particular,
GFP-K72 generated the strongest emission signal recorded inside
A549 cells. Interestingly, we detected the signal of GFP-K72 even
over an extended period of time up to 48 h (Fig. 2C). These obser-
vations are in good agreement with the quantitative uptake data
obtained by ﬂuorimetry and prove efﬁcient protein uptake medi-
ated by positively supercharged ELP tags bearing 36 and 72 positive
charges. Moreover, in the presence of serum, no aggregation with
serum proteins was observed under the microscope for any GFPe
ELP fusion protein, which is essential for any application in vivo.
3.4. Cytotoxicity study
Cytotoxicity of all the GFP variants was assessed under the same
conditions as used for the cell uptake experiments. The assay is
based on the quantiﬁcation of ATP, an indicator of metabolically
Fig. 4. Effects of inhibitors on internalization of GFP-K72. Cells were pretreated under
4 C or with ﬁlipin (FIL), chlorpromazine (CPZ) and amiloride (AML) and subsequently
incubated with GFP-K72 for 2 h (for the details see Materials and methods). The
ﬂuorescence from GFP-K72 was measured by microplate reader. The ﬂuorescence in-
tensity in positive control cells was set as 100%. Mean values and standard deviation
were obtained from triplicate experiments. One-way ANOVA test followed by Dun-
nett’s test was carried out to determine the statistical signiﬁcance of the data
(*P < 0.05; **P < 0.01).
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of ATP is directly proportional to the number of cells present in
culture. As shown in Fig. 2B, cells showed no loss in cell viability
when incubated for 24 h with GFP-derivates below a concentration
of 1 mM, and even for higher concentrations of up to 10 mM no effect
of the ELP length on cytotoxicity was observed. In comparison,
positively charged polymers such as poly-L-lysine and poly(-
ethylene)imine very often display signiﬁcant cytotoxicities,
revealing that the charge density plays an important role [40]. Even
a short polyarginine tag showed an EC50 value of about 9 mM in
A549 cells [41]. Systematic studies suggested that aggregation as
well as disruption of membrane integrity are reasons for cytotox-
icity [42] Strategies such as masking of positive charges have been
applied to decrease cytotoxicity [43,44]. However, ﬁne-tuning the
number and density of positive charges for cell uptake is not always
trivial. In contrast, polycationic proteins, such as supercharged al-
bumins, were applied in comparatively high quantities before cell
toxicity was observedwhich has been attributed to their lowcharge
density dissipated within a larger volume [45,46]. Therefore, the
cationic ELP tags and in particular GFP-K72 offers an increased
molecular weight and hydrodynamic volume, lower charge den-
sities and no increase in cytotoxicity compared with the conven-
tional polycationic tags, such as the polyarginine tag, which display
high density of positive charges. The increase of molecular weight
induced by the tag could potentially induce an enhanced blood
circulation of the respective protein or an accumulation in tumor
tissue via the EPR-effect, which are both known to be size depen-
dent. These aspects will be addressed in future studies.
3.5. Cell uptake pathway
Several mechanisms are known by which macromolecules can
enter cells, including energy-dependent mechanisms, such as
endocytosis or macropinocytosis as well as other non-energy
dependent mechanisms [47]. Investigation of the cell uptake
pathway represents an essential step to understand the intracel-
lular fate of a molecule and assess its intracellular functions. Wehave studied the uptake pathway of GFP-K72 tagged with super-
charged ELP in A549 cells. GFP-K72 was selected because it dis-
played the most signiﬁcant cell uptake. The energy dependency of
cell uptake was investigated by incubation at 4 C and 37 C. In-
cubation at the lower temperature resulted in a signiﬁcant, about
85% reduction of the entire cell uptake (Fig. 4), indicating that GFP-
K72 uptake mainly proceeded through energy-dependent path-
ways. However 15% of cell uptake remained at 4 C indicating that
energy-independent direct translocation may play a minor role.
Different endocytosis inhibitors were then applied to determine
the speciﬁc energy-dependent endocytic pathway by which GFP-
K72 is internalized. Cells were pre-incubated with inhibitors for
30 min followed by incubating with 1 mM of GFP-K72 for 2 h. The
cell uptake was assayed by a ﬂuorescence microplate reader as
described above. We observed the most signiﬁcant suppression of
GFP-K72 uptake with Filipin (FIL), which is known to inhibit
caveolae-mediated endocytosis [48]. After the application of only
0.1 mg/mL FIL a >70% reduction of cellular uptake was observed. In
comparison, only insigniﬁcant effects were detected upon treat-
ment with the clathrin-mediated endocytosis inhibitor chlor-
promazine hydrochloride (CPMZ) [49] or the macropinocytosis
inhibitor amiloride (Fig. 4). These observations suggest that cell
uptake of GFP-K72 mainly proceeds through caveolae-mediated
endocytic pathways and that clathrin-mediated endocytosis and
macropinocytosis only play a minor role. It has been reported
previously that particles internalized via clathrin-mediated endo-
cytosis are delivered to the lysosomes whereas uptake via caveolae
allows escaping lysosomal pathways and trafﬁcking to the endo-
plasmic reticulum of the cell [50,51]. In view of the delivery of
therapeutic proteins, it is an attractive feature that ELP super-
charged tags facilitate cell uptake via the caveolae-mediated
pathway, as this should minimize protein degradation in lyso-
somes. This feature is supported by the fact that the ﬂuorescence of
the GFP variants was observed inside the cells even after 48 h of
incubation.
In comparison, some short CPPs were found to enter cells via
macropinocytosis [52,53] and folded supercharged proteins
including GFP were taken up predominantly by clathrin-dependent
endocytosis [38]. In the context of ELP uptake, previously neutral
variants were reported to penetrate cells via a caveolae-
independent endocytic mechanism [26]. These uptake mecha-
nisms are in stark contrast to the internalization of our super-
charged ELP fusions indicating how the charge, the molecular
weight and the folding state of the tag are important for deter-
mining uptake pathways. In general, the cellular uptake pathways
studied in the literature are difﬁcult to compare. Factors such as the
concentration of peptides, the ionic strength of the medium [54],
the nature of the cell lines and the presence and type of cargo
[55,56] have a signiﬁcant inﬂuence on the uptake mechanism.
4. Conclusions
In summary, we have shown the expression of the ﬂuorescent
reporter protein GFP bearing rationally designed ELP supercharged
tags of varying lengths with an unprecedented number of charges.
Furthermore, we observed that their cellular uptake strongly de-
pends on the number of positive charges present in the tag. The
most positive charged protein, GFP-K72 (theoretical positive net
charge: 72), exhibited a roughly six fold increase in uptake
compared to unmodiﬁed GFP, and indeed a signiﬁcant amount of
GFP was detected inside the cells even after 48 h. Investigating the
mechanism, we showed that cell uptake proceeds primarily via
caveolae-mediated endocytosis. Finally, we believe that the facile
introduction of supercharged elastin-like tags by genetic engi-
neering has a high potential to improve cellular uptake and critical
D. Pesce et al. / Biomaterials 34 (2013) 4360e43674366pharmacokinetic parameters. Therefore, such tags complement
existing poly-L-arginine or poly-L-lysine sequences as well as folded
supercharged proteins. Due to the growing importance of protein
therapeutics the discovery of tags improving their delivery is of
high signiﬁcance to allow a better translation into preclinical and
clinical research.
Acknowledgment
T.W. thanks the German Research Foundation (DFG) under grant
P3246029 and the Volkswagenstiftung (Aktenzeichen 86 366) for
their ﬁnancial support of this work.
A.H. acknowledges ﬁnancial support from the EU (ERC starting
grant NUCLEOPOLY), from NWO (VICI grant, ECHO grant) and from
the Zernike Institute for Advanced Materials.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.biomaterials.2013.02.038.
References
[1] Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there?
Nat Rev Drug Discov 2006;5:993e6.
[2] Thompson DB, Cronican JJ, Liu DR. Engineering and identifying supercharged
proteins for macromolecule delivery into mammalian cells. Meth Enzymol
2012;503:293e319.
[3] Zelphati O, Wang Y, Kitada S, Reed JC, Felgner PL, Corbeil J. Intracellular de-
livery of proteins with a new lipid-mediated delivery system. J Biol Chem
2001;276:35103e10.
[4] Hasadsri L, Kreuter J, Hattori H, Iwasaki T, George JM. Functional protein de-
livery into neurons using polymeric nanoparticles. J Biol Chem 2009;284:
6972e81.
[5] Holm T, Johansson H, Lundberg P, Pooga M, Lindgren M, Langel Ü. Studying
the uptake of cell-penetrating peptides. Nat Protoc 2006;1:1001e5.
[6] Rizk SS, Luchniak A, Uysal S, Brawley CM, Rock RS, Kossiakoff AA. An engi-
neered substance P variant for receptor-mediated delivery of synthetic anti-
bodies into tumor cells. Proc Natl Acad Sci U S A 2009;106:11011e5.
[7] Heitz F, Morris MC, Divita G. Twenty years of cell-penetrating peptides: from
molecular mechanisms to therapeutics. Br J Pharmacol 2009;157:195e206.
[8] Gomez JA, Gama V, Yoshida T, Sun W, Hayes P, Leskov K, et al. Bax-inhibiting
peptides derived from Ku70 and cell-penetrating pentapeptides. Biochem Soc
Trans 2007;35:797e801.
[9] Shen WC, Ryser HJ. Conjugation of poly-L-lysine to albumin and horseradish
peroxidase: a novel method of enhancing the cellular uptake of proteins. Proc
Natl Acad Sci U S A 1978;75:1872e6.
[10] Chen L, Wright LR, Chen CH, Oliver SF, Wender PA, Mochly-Rosen D. Molec-
ular transporters for peptides: delivery of a cardioprotective epsilonPKC
agonist peptide into cells and intact ischemic heart using a transport system,
R(7). Chem Biol 2001;8:1123e9.
[11] Chen L, Hahn H, Wu G, Chen CH, Liron T, Schechtman D, et al. Opposing
cardioprotective actions and parallel hypertrophic effects of delta PKC and
epsilon PKC. Proc Natl Acad Sci U S A 2001;98:11114e9.
[12] Rothbard JB, Garlington S, Lin Q, Kirschberg T, Kreider E, McGrane PL, et al.
Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery
and inhibition of inﬂammation. Nat Med 2000;6:1253e7.
[13] Jin LH, Bahn JH, Eum WS, Kwon HY, Jang SH, Han KH, et al. Transduction of
human catalase mediated by an HIV-1 TAT protein basic domain and arginine-
rich peptides into mammalian cells. Free Radic Biol Med 2001;31:1509e19.
[14] Su Y, Doherty T, Waring AJ, Ruchala P, Hong M. Roles of arginine and lysine
residues in the translocation of a cell-penetrating peptide from (13)C, (31)P,
and (19)F solid-state NMR. Biochemistry 2009;48:4587e95.
[15] Su Y, Li S, Hong M. Cationic membrane peptides: atomic-level insight of
structure-activity relationships from solid-state NMR. Amino Acids 2012;44:
821e33.
[16] Hudecz F, Gaál D, Kurucz I, Lányi Á, Kovács AL, Mezö G, et al. Carrier design:
cytotoxicity and immunogenicity of synthetic branched polypeptides with
poly(L-lysine) backbone. J Control Release 1992;19:231e43.
[17] Simeonov P, Berger-Hoffmann R, Hoffmann R, Sträter N, Zuchner T. Surface
supercharged human enteropeptidase light chain shows improved solubility
and refolding yield. Protein Eng Des Sel 2011;24:261e8.
[18] Cronican JJ, Thompson DB, Beier KT, McNaughton BR, Cepko CL, Liu DR. Potent
delivery of functional proteins into mammalian cells in vitro and in vivo using
a supercharged protein. ACS Chem Biol 2010;5:747e52.
[19] Cronican JJ, Beier KT, Davis TN, Tseng J-C, Li W, Thompson DB, et al. A class of
human proteins that deliver functional proteins into mammalian cells in vitro
and in vivo. Chem Biol 2011;18:833e8.[20] Lawrence MS, Phillips KJ, Liu DR. Supercharging proteins can impart unusual
resilience. J Am Chem Soc 2007;129:10110e2.
[21] Kolbe A, del Mercato LL, Abbasi AZ, Rivera Gil P, Gorzini SJ, Huibers WHC, et al.
De novo design of supercharged, unfolded protein polymers, and their as-
sembly into supramolecular aggregates. Macromol Rapid Commun 2010;32:
186e90.
[22] Nettles DL, Chilkoti A, Setton LA. Applications of elastin-like polypeptides in
tissue engineering. Adv Drug Deliv Rev 2010;62:1479e85.
[23] Megeed Z, Haider M, Li D, O’Malley BW, Cappello J, Ghandehari H. In vitro and
in vivo evaluation of recombinant silk-elastin like hydrogels for cancer gene
therapy. J Control Release 2004;94:433e45.
[24] Dandu R, Ghandehari H. Delivery of bioactive agents from recombinant
polymers. Prog Polym Sci 2007;32:1008e30.
[25] MacEwan SR, Chilkoti A. Elastin-like polypeptides: biomedical applications of
tunable biopolymers. Biopolymers 2010;94:60e77.
[26] Bidwell GL, Raucher D. Cell penetrating elastin-like polypeptides for thera-
peutic peptide delivery. Adv Drug Deliv Rev 2010;62:1486e96.
[27] Na K, Lee SA, Jung SH, Hyun J, Shin BC. Elastin-like polypeptide modiﬁed li-
posomes for enhancing cellular uptake into tumor cells. Colloids Surf B
2012;91:130e6.
[28] Meyer D, Chilkoti A. Genetically encoded synthesis of protein-based polymers
with precisely speciﬁed molecular weight and sequence by recursive direc-
tional ligation: examples from the elastin-like polypeptide system. Bio-
macromolecules 2002;3:357e67.
[29] Ren Y, Wong SM, Lim L-Y. Folic acid-conjugated protein cages of a plant virus:
a novel delivery platform for doxorubicin. Bioconjug Chem 2007;18:836e43.
[30] Liu SQ, Tong YW, Yang Y-Y. Incorporation and in vitro release of doxorubicin
in thermally sensitive micelles made from poly(N-isopropylacrylamide-co-N,
N-dimethylacrylamide)-b-poly(D, L-lactide-co-glycolide) with varying com-
positions. Biomaterials 2005;26:5064e74.
[31] Lacerda L, Russier J, Pastorin G, Herrero MA, Venturelli E, Dumortier H, et al.
Translocation mechanisms of chemically functionalised carbon nanotubes
across plasma membranes. Biomaterials 2012;33:3334e43.
[32] Zelikin AN, Breheney K, Robert R, Tjipto E, Wark K. Cytotoxicity and inter-
nalization of polymer hydrogel capsules by mammalian cells. Bio-
macromolecules 2010;11:2123e9.
[33] Perumal OP, Inapagolla R, Kannan S, Kannan RM. The effect of surface func-
tionality on cellular trafﬁcking of dendrimers. Biomaterials 2008;29:3469e76.
[34] Puri V, Watanabe R, Singh RD, Dominguez M, Brown JC, Wheatley CL, et al.
Clathrin-dependent and -independent internalization of plasma membrane
sphingolipids initiates two Golgi targeting pathways. J Cell Biol 2001;154:
535e47.
[35] Lin R, Shi Ng L, Wang C-H. In vitro study of anticancer drug doxorubicin in
PLGA-based microparticles. Biomaterials 2005;26:4476e85.
[36] Massodi I, Moktan S, Rawat A, Bidwell GL, Raucher D. Inhibition of ovarian
cancer cell proliferation by a cell cycle inhibitory peptide fused to a thermally
responsive polypeptide carrier. Int J Cancer 2010;126:533e44.
[37] Shamji MF, Chen J, Friedman AH, Richardson WJ, Chilkoti A, Setton LA. Syn-
thesis and characterization of a thermally-responsive tumor necrosis factor
antagonist. J Control Release 2008;129:179e86.
[38] Thompson DB, Villaseñor R, Dorr BM, Zerial M, Liu DR. Cellular uptake
mechanisms and endosomal trafﬁcking of supercharged proteins. Chem Biol
2012;19:831e43.
[39] Godbey WT, Wu KK, Mikos AG. Tracking the intracellular path of poly (eth-
ylenimine)/DNA complexes for gene delivery. Proc Natl Acad Sci U S A
1999;96:5177e81.
[40] Beyerle A, Merkel O, Stoeger T, Kissel T. PEGylation affects cytotoxicity and
cell-compatibility of poly(ethylene imine) for lung application: structuree
function relationships. Toxicol Appl Pharmacol 2010;242:146e54.
[41] Jones SW, Christison R, Bundell K, Voyce CJ, Brockbank SMV, Newham P, et al.
Characterisation of cell-penetrating peptide-mediated peptide delivery. Br J
Pharmacol 2005;145:1093e102.
[42] Leroueil PR, Hong S, Mecke A, Baker JR, Orr BG, Banaszak Holl MM. Nano-
particle interaction with biological membranes: does nanotechnology present
a Janus face? Acc Chem Res 2007;40:335e42.
[43] Choi YH, Liu F, Park JS, Kim SW. Lactose-poly(ethylene glycol)-grafted poly-L-
lysine as hepatoma cell-targeted gene carrier. Bioconjug Chem1998;9:708e18.
[44] Lee H, Jeong JH, Park TG. PEG grafted polylysine with fusogenic peptide for
gene delivery: high transfection efﬁciency with low cytotoxicity. J Control
Release 2002;79:283e91.
[45] Choksakulnimitr S, Masuda S, Tokuda H, Takakura Y, Hashida M. In vitro
cytotoxicity of macromolecules in different cell culture systems. J Control
Release 1995;34:233e41.
[46] Eisele K, Gropeanu RA, Zehendner CM, Rouhanipour A, Ramanathan A,
Mihov G, et al. Fine-tuning DNA/albumin polyelectrolyte interactions to
produce the efﬁcient transfection agent cBSA-147. Biomaterials 2010;31:
8789e801.
[47] Canton I, Battaglia G. Endocytosis at the nanoscale. Chem Soc Rev 2012;41:
2718e39.
[48] Schnitzer JE, Oh P, Pinney E, Allard J. Filipin-sensitive caveolae-mediated
transport in endothelium: reduced transcytosis, scavenger endocytosis, and
capillary permeability of select macromolecules. J Cell Biol 1994;127:1217e32.
[49] Wang LH, Rothberg KG, Anderson RG. Mis-assembly of clathrin lattices on
endosomes reveals a regulatory switch for coated pit formation. J Cell Biol
1993;123:1107e17.
D. Pesce et al. / Biomaterials 34 (2013) 4360e4367 4367[50] Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of
particles via the pathways of clathrin- and caveolae-mediated endocytosis.
Biochem J 2004;377:159e69.
[51] Shin JS, Abraham SN. Caveolae as portals of entry for microbes. Microb Infect
2001;3:755e61.
[52] Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide en-
hances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat
Med 2004;10:310e5.
[53] Nakase I, Tadokoro A, Kawabata N, Takeuchi T, Katoh H, Hiramoto K, et al.
Interaction of arginine-rich peptides with membrane-associated pro-
teoglycans is crucial for induction of actin organization and macropinocytosis.
Biochemistry 2007;46:492e501.[54] Guterstam P, Madani F, Hirose H, Takeuchi T, Futaki S, Andaloussi El S,
et al. Elucidating cell-penetrating peptide mechanisms of action for mem-
brane interaction, cellular uptake, and translocation utilizing the hydro-
phobic counter-anion pyrenebutyrate. Biochim Biophys Acta 2009;1788:
2509e17.
[55] Säälik P, Elmquist A, Hansen M, Padari K, Saar K, Viht K, et al. Protein cargo
delivery properties of cell-penetrating peptides. A comparative study. Bio-
conjug Chem 2004;15:1246e53.
[56] Richard JP, Melikov K, Brooks H, Prevot P, Lebleu B, Chernomordik LV.
Cellular uptake of unconjugated TAT peptide involves clathrin-dependent
endocytosis and heparan sulfate receptors. J Biol Chem 2005;280:
15300e6.
